Data | Hora | Fonte | Título | Código | Companhia |
13/10/2009 | 17:05 | Business Wire | Allos Therapeutics Announces Closing of Public Offering | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
13/10/2009 | 07:40 | Marketwired | ELNK, HERO, ABAT, NTAP, DBRN and ALTH Receives Analytical Coverage from WallStSense.com | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/10/2009 | 18:08 | Edgar (US Regulatory) | Prospectus filed pursuant to Rule 424(b)(5) (424B5) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/10/2009 | 07:19 | Edgar (US Regulatory) | Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/10/2009 | 07:14 | Business Wire | Allos Therapeutics Announces Pricing of Public Offering of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/10/2009 | 17:06 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/10/2009 | 17:01 | Business Wire | Allos Therapeutics Announces Proposed Public Offering of Common Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
05/10/2009 | 08:00 | Business Wire | Allos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/10/2009 | 18:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/10/2009 | 07:36 | Marketwired | RothmanResearch.com Stock Review for SCG, CA, NE, MKC, COL and ALTH | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
25/09/2009 | 08:00 | Business Wire | Allos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
11/09/2009 | 17:15 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/09/2009 | 19:09 | Business Wire | Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN™ (pralatrexate) for the Trea... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
02/09/2009 | 07:00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/09/2009 | 10:05 | Edgar (US Regulatory) | Post-Effective Amendment to Registration Statement (POS AM) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
01/09/2009 | 09:00 | Business Wire | Allos Therapeutics to Hold Post Advisory Committee Conference Call | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
31/08/2009 | 10:31 | PR Newswire (US) | Seven Summits Research Releases Comments on Boeing, Joy Global, Ciena Corporation, TakeTwo Interactive and Allos Therapeutics | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
28/08/2009 | 14:27 | Dow Jones News | FDA Has Several Issues With Allos Data For Folotyn | NASDAQ:ALTH | Allos Therapeutics Inc. |
14/08/2009 | 17:16 | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
10/08/2009 | 11:25 | Business Wire | Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Ref... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/08/2009 | 18:16 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
04/08/2009 | 17:00 | Business Wire | Allos Therapeutics Reports Second Quarter 2009 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
23/07/2009 | 11:06 | Business Wire | Allos Therapeutics Launches Peripheral T-Cell Lymphoma Website | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
22/07/2009 | 09:00 | Business Wire | Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/07/2009 | 09:04 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (S-8) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
20/07/2009 | 09:00 | Edgar (US Regulatory) | Securities Registration Statement (simplified form) (S-3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/07/2009 | 09:07 | Marketwired | BridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXM | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
07/07/2009 | 09:00 | Business Wire | Allos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
29/06/2009 | 09:40 | PR Newswire (US) | InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren Reso | NASDAQ:ALTH | |
02/06/2009 | 07:05 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |